9OOI | pdb_00009ooi

Crystal structure of dihydrofolate reductase (DHFR) from the filarial nematode W. bancrofti in complex with NADPH and antifolate 2-({4-[(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]benzene-1-carbonyl}amino)benzoic acid (OG7 or TSD001)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.91 Å
  • R-Value Free: 
    0.292 (Depositor), 0.296 (DCC) 
  • R-Value Work: 
    0.257 (Depositor), 0.261 (DCC) 
  • R-Value Observed: 
    0.259 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

A virtual screening strategy to repurpose antifolate compounds as W. Bancrofti DHFR inhibitors.

Kwarteng, S.Wilhelm, J.Salama, M.Salama, M.Hollander, K.Anderson, K.S.Goodey, N.M.Frey, K.M.

(2025) Bioorg Med Chem Lett : 130370-130370

  • DOI: https://doi.org/10.1016/j.bmcl.2025.130370
  • Primary Citation of Related Structures:  
    9MLM, 9MLT, 9ONI, 9OOI

  • PubMed Abstract: 

    Lymphatic filariasis, caused by Wuchereria bancrofti, remains a global health challenge. The enzyme Wuchereria bancrofti dihydrofolate reductase (WbDHFR) is a potential therapeutic target due to DHFR's critical role in folate metabolism and DNA synthesis. In this study, we employed a virtual screening workflow to repurpose antifolate compounds as WbDHFR inhibitors. Using structural data from the Protein Data Bank, we constructed a library of 194 antifolates and docked them to the WbDHFR folate binding site. Compounds methotrexate, TSD001, TSD10, and TSD25, with docking scores ranging from -9 to -8 kcal/mol, were selected for experimental validation. Inhibition assays demonstrated nanomolar activity with methotrexate and low micromolar activity with TSD001 (K i  = 1 μM). Crystallographic studies revealed high-resolution structures of WbDHFR in complex with methotrexate (2.4 Å), TSD001 (2.9 Å), TSD10 (1.8 Å) and TSD25 (2.1 Å), providing detailed insights into binding interactions. Major interactions common for the inhibitors include hydrogen bonds with Glu32. These findings highlight the effectiveness of the virtual screening workflow and establish a foundation for optimizing these antifolate compounds for WbDHFR inhibition. This workflow can be applied to other parasitic DHFR enzymes, advancing drug discovery efforts against neglected tropical diseases.


  • Organizational Affiliation
    • Department of Chemistry and Biochemistry, Montclair State University, Montclair, NJ, USA.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
dihydrofolate reductase
A, B, C
193Wuchereria bancroftiMutation(s): 0 
EC: 1.5.1.3
UniProt
Find proteins for A0AAF5PZP7 (Wuchereria bancrofti)
Explore A0AAF5PZP7 
Go to UniProtKB:  A0AAF5PZP7
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupA0AAF5PZP7
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.91 Å
  • R-Value Free:  0.292 (Depositor), 0.296 (DCC) 
  • R-Value Work:  0.257 (Depositor), 0.261 (DCC) 
  • R-Value Observed: 0.259 (Depositor) 
Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 134.168α = 90
b = 232.027β = 90
c = 75.645γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
PDB_EXTRACTdata extraction
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not fundedUnited States--

Revision History  (Full details and data files)

  • Version 1.0: 2025-08-27
    Type: Initial release